Effect of haloperidol decanoate on the cardiovascular system.
Rapid speed electrocardiograms were recorded in 13 chronic schizophrenic patients before, and at regular intervals during a six-month trial of haloperidol decanoate. Measurements of conduction intervals in the EEG were carried out blind to patient and to assessment interval. No significant changes in heart rate; PR, QRS on QTc intervals; or T-wave height were found. Neither was there a significant change in the blood pressure. The findings confirm that haloperidol does not have clinically relevant cardiac effects when given in therapeutic doses to physically healthy individuals.
Department of Neuropsychiatry, Hirosaki University School of Medicine, Japan.
S
S
Kaneko
J G
JG
Edwards
A
A
Goldie
Y
Y
Fukushima
T
T
Sato
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; C033563:haloperidol decanoate; D006220:Haloperidol